Preston MA, et al. - In view of the predictive value of midlife prostate-specific antigen (PSA) levels in assessing long-term prostate cancer () mortality among white men, researchers investigated if baseline PSA level in midlife could predict the risk of aggressive PCa in black men. They performed a nested case-control study among black men in the Southern Community Cohort Study, which enrolled patients between 2002 and 2009. PSA levels in midlife among these men predicted total and aggressive PCa (Gleason ≥7, American Joint Committee on Cancer stage III/IV, or PCa-specific death) robustly. For aggressive cancer, they observed odds ratios of 174 for 40–54 year and 51.8 for 55–64 year.